NRX Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
NRXP$2.380.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| | December 31, | |||||
| · · 2023 · · 2022 | ||||||
| · · · · · | ||||||
| ASSETS · · | ||||||
| Current assets: · · · | ||||||
| Cash and cash equivalents | | $4,595 | | $20,054 | ||
| Prepaid expenses and other current assets | | 2,289 | | 5,741 | ||
| Total current assets | | 6,884 | | 25,795 | ||
| Other assets | | 431 | | 21 | ||
| Total assets | | $7,315 | | $25,816 | ||
| LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $4,632 | | $2,076 | ||
| Accrued and other current liabilities | | 4,714 | | 4,855 | ||
| Accrued clinical site costs | | 524 | | 914 | ||
| Convertible note payable and accrued interest - short term | | | 9,161 | | | 7,703 |
| Warrant liabilities | | | 17 | | | 37 |
| Total current liabilities | | 19,048 | | 15,585 | ||
| Convertible note payable and accrued interest - long term | | — | | 2,822 | ||
| Total liabilities | | $19,048 | | $18,407 | ||
| | | | | | | |
| Commitments and Contingencies (Note 8) | | | | | | |
| | | | | | | |
| Stockholders’ (deficit) equity: | | | ||||
| Preferred stock, $0.001 par value, 50,000,000 shares authorized; | | $— | | $— | ||
| Series A convertible preferred stock, $0.001 par value, 12,000,000 shares authorized; 3,000,000 and 0 shares issued and outstanding at December 31, 2023 and 2022, respectively | | | 3 | | | — |
| Common stock, $0.001 par value, 500,000,000 shares authorized; 83,919,554 and 66,442,989 shares issued and outstanding at December 31, 2023 and 2022, respectively | | 84 | | 67 | ||
| Additional paid-in capital | | 241,330 | | 230,339 | ||
| Accumulated other comprehensive loss | | | (3) | | — | |
| Accumulated deficit | | (253,147) | | (222,997) | ||
| Total stockholders’ (deficit) equity | | (11,733) | | 7,409 | ||
| Total liabilities and stockholders' (deficit) equity | | $7,315 | | $25,816 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.